Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

“We did see a statistically significant improvement in DFS in the experimental arm that included pembrolizumab.”

Yvonne Mowery, MD, PhD, associate professor, Department of Radiation Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, radiation oncologist, Mary Hillman Jennings Radiation Oncology, UPMC Shadyside, discusses findings from the phase 2 SU2C-SARC032 trial (NCT03092323) investigating perioperative pembrolizumab (Keytruda) in combination with standard-of-care (SOC) radiotherapy followed by surgery vs radiotherapy and surgery alone in patients with soft tissue sarcoma. 

This trial demonstrated significant improvements in disease-free survival (DFS) with the addition of pembrolizumab to SOC, Mowery begins. The 2-year DFS rate, which served as the trial’s primary end point, was 67% (90% CI, 58%-78%) in the pembrolizumab arm (n = 64) vs 52% (90% CI, 42%-64%) in the SOC alone arm (n = 63), translating to an absolute improvement of 15% (HR, 0.61; 90% CI, 0.39-0.96). 

Following the presentation of early findings from this trial at the 2024 ASCO Annual Meeting, many oncologists began integrating pembrolizumab into their clinical practice for the treatment of patients with soft tissue sarcoma, including in settings where chemotherapy is less commonly used, Mowery says. In the trial, the greatest benefit with the addition of pembrolizumab to SOC was observed in patients with grade 3 undifferentiated pleomorphic sarcoma or dedifferentiated pleomorphic liposarcoma, she notes. Many patients with these high-risk subtypes now receive perioperative pembrolizumab as part of their treatment plan, she explains. 

Future directions for optimizing the management of soft tissue sarcoma include exploring the integration of immunotherapy with chemotherapy, according to Mowery. Although chemotherapy’s potential immunosuppressive effects could theoretically counteract the efficacy of immunotherapy, certain chemotherapeutic agents used in soft tissue sarcoma have been shown to induce immunogenic cell death, which could result in a cooperative or synergistic effect between these 2 classes of agents, she adds. However, this hypothesis requires experimental validation, as the SU2C-SARC032 trial did not evaluate the use of pembrolizumab plus chemotherapy, she cautions. 

Another area of interest for research in soft tissue sarcoma involves dual immune checkpoint blockade, Mowery emphasizes. Pembrolizumab targets PD-1, and early studies have explored combining anti-PD-1 therapy with anti-CTLA-4 therapy, she reports. This combination has shown promise in other malignancies and is being considered for future randomized trials in soft tissue sarcoma, she concludes.

Videos

Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Yvonne Mowery, MD, PhD, about the phase 2 SU2C-SARC032 trial (NCT03092323) investigating the addition of pembrolizumab to preoperative radiotherapy and surgery in patients with soft-tissue sarcoma. Dr Mowey is a physician scientist and an associate professor of radiation oncology at the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania. 

In our exclusive interview, Dr Mowery discussed unmet needs for patients with soft-tissue sarcoma that prompted the initiation of this research, key efficacy and safety findings from the trial, and potential next steps for investigating the treatment regimen in this patient population. 

That’s all we have for today! Thank you for listening to this episode of 

. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Mowery discusses the SU2C-SARC032 trial of pembrolizumab plus preoperative radiotherapy and surgery in patients with soft-tissue sarcoma. 

Yvonne Mowery, MD, PhD

Articles

Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD